By Iain Gilbert
Date: Wednesday 23 Sep 2026
(Sharecast News) - Drugmaker Astrazeneca said on Wednesday that its Trixeo Aerosphere candidate has been approved in the European Union as a maintenance treatment for asthma in patients aged 12 and over.
| Trixeo approved in EU for asthma | 23-Sep-2026 | 07:00 | RNS |
| Klygefa recommended for EU approval by CHMP | 21-Sep-2026 | 07:05 | RNS |
| Enhertu recommended for approval in EU in early BC | 21-Sep-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 18-Sep-2026 | 11:00 | RNS |
| Director/PDMR Shareholding | 15-Sep-2026 | 15:05 | RNS |
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 12,400.00p |
| Change Today | -30.00p |
| % Change | -0.24 % |
| 52 Week High | 15,316.00 |
| 52 Week Low | 10,956.00 |
| Volume | 2,097,116 |
| Shares Issued | 1,551.04m |
| Market Cap | £192,329m |
| Beta | 0.00 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 8 |
| Neutral | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 24 |

| Latest | Previous | |
|---|---|---|
| 1st Interim | 2nd Interim | |
| Ex-Div | 06-Aug-26 | 19-Feb-26 |
| Paid | 08-Sep-26 | 23-Mar-26 |
| Amount | 106.00¢ | 217.00¢ |
| Time | Volume / Share Price |
| 16:01 | 141,000 @ 12,459.00p |
| 16:37 | 20 @ 12,400.00p |
| 16:37 | 8 @ 12,400.00p |
| 16:37 | 42 @ 12,400.00p |
| 16:37 | 49 @ 12,400.00p |
You are here: research